Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Biobased Chemicals

Ginkgo to cut costs as pandemic-related business slows

by Matt Blois
May 16, 2024 | A version of this story appeared in Volume 102, Issue 15

 

Ginkgo Bioworks is cutting costs and laying off staff after losing $166 million in the first quarter. Revenue from its disease-monitoring business surged during the COVID-19 pandemic but was down more than 50% compared with the first quarter of 2023. Its business that engineers microbes for biomanufacturing customers slowed because fewer start-ups were seeking help. Ginkgo plans to cut spending on laboratory space by 60% and labor by 25% over the next year. The company’s share price has fallen more than 90% since 2021. It could be delisted from the New York Stock Exchange if the price doesn’t improve.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.